Boston Common Asset Management’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$25.5M Sell
198,228
-452
-0.2% -$52.9K 1.51% 13
2026
Q1
$23.9M Sell
198,680
-4,527
-2% -$523K 1.54% 13
2025
Q4
$21.4M Sell
203,207
-44,511
-18% -$4.18M 1.29% 14
2025
Q3
$20.8M Sell
247,718
-22,009
-8% -$1.81M 0.58% 56
2025
Q2
$21.4M Sell
269,727
-30,618
-10% -$2.43M 0.6% 56
2025
Q1
$27M Sell
300,345
-19,346
-6% -$1.81M 0.82% 30
2024
Q4
$31.8M Buy
319,691
+119,575
+60% +$12.3M 0.93% 21
2024
Q3
$22.7M Sell
200,116
-13,077
-6% -$1.55M 0.59% 57
2024
Q2
$26.4M Sell
213,193
-28,675
-12% -$3.69M 0.68% 44
2024
Q1
$31.9M Sell
241,868
-84,680
-26% -$10.4M 0.76% 39
2023
Q4
$35.6M Sell
326,548
-73,026
-18% -$7.58M 0.81% 39
2023
Q3
$41.1M Sell
399,574
-8,893
-2% -$959K 0.98% 20
2023
Q2
$47.1M Sell
408,467
-159,451
-28% -$18.1M 1.01% 14
2023
Q1
$60.4M Sell
567,918
-82,777
-13% -$8.94M 1.26% 8
2022
Q4
$72.2M Buy
650,695
+24,752
+4% +$2.53M 3.45% 1
2022
Q3
$53.9M Buy
625,943
+24,118
+4% +$2.15M 2.83% 1
2022
Q2
$54.9M Sell
601,825
-41,265
-6% -$3.66M 2.73% 1
2022
Q1
$52.8M Buy
643,090
+290,975
+83% +$22.9M 2.28% 3
2021
Q4
$27M Sell
352,115
-52,198
-13% -$4.16M 1.09% 26
2021
Q3
$30.4M Buy
404,313
+53,102
+15% +$4.04M 1.31% 21
2021
Q2
$27.3M Buy
351,211
+16,762
+5% +$1.25M 1.17% 28
2021
Q1
$24.6M Buy
334,449
+23,108
+7% +$1.7M 1.55% 12
2020
Q4
$24.3M Buy
311,341
+134,261
+76% +$10.3M 1.7% 11
2020
Q3
$14M Buy
177,080
+58
+0% +$4.54K 1.33% 15
2020
Q2
$13.1M Buy
177,022
+15,880
+10% +$1.2M 1.39% 17
2020
Q1
$11.8M Buy
161,142
+21,413
+15% +$1.68M 1.67% 14
2019
Q4
$12.1M Sell
139,729
-15,429
-10% -$1.27M 1.41% 15
2019
Q3
$12.5M Sell
155,158
-39,854
-20% -$3.19M 1.54% 12
2019
Q2
$15.6M Sell
195,012
-4,631
-2% -$355K 1.94% 9
2019
Q1
$15.8M Buy
199,643
+3,951
+2% +$296K 2.06% 10
2018
Q4
$14.3M Sell
195,692
-1,467
-0.7% -$104K 2.08% 11
2018
Q3
$13.3M Sell
197,159
-6,930
-3% -$442K 1.66% 13
2018
Q2
$11.8M Buy
204,089
+7,552
+4% +$426K 1.46% 15
2018
Q1
$10.2M Buy
196,537
+7,556
+4% +$408K 1.2% 18
2017
Q4
$10.1M Buy
188,981
+9,759
+5% +$541K 1.2% 16
2017
Q3
$10.9M Buy
179,222
+6,818
+4% +$413K 1.36% 16
2017
Q2
$10.5M Buy
172,404
+4,449
+3% +$271K 1.39% 16
2017
Q1
$10.2M Sell
167,955
-2,270
-1% -$138K 1.38% 15
2016
Q4
$9.56M Buy
170,225
+2,148
+1% +$126K 1.4% 16
2016
Q3
$10M Buy
168,077
+1,010
+0.6% +$59.1K 0.54% 73
2016
Q2
$9.18M Sell
167,067
-4,669
-3% -$248K 0.53% 74
2016
Q1
$8.67M Buy
171,736
+20,599
+14% +$1.01M 0.49% 76
2015
Q4
$7.62M Sell
151,137
-6,508
-4% -$328K 0.43% 82
2015
Q3
$7.43M Buy
157,645
+4,820
+3% +$256K 0.45% 83
2015
Q2
$8.3M Sell
152,825
-7,346
-5% -$412K 0.44% 82
2015
Q1
$8.79M Buy
160,171
+676
+0.4% +$38.3K 0.47% 83
2014
Q4
$8.64M Sell
159,495
-992
-0.6% -$55.3K 0.48% 83
2014
Q3
$9.08M Buy
160,487
+6,733
+4% +$378K 0.51% 83
2014
Q2
$8.49M Buy
153,754
+25,999
+20% +$1.42M 0.46% 88
2014
Q1
$6.92M Buy
127,755
+26
+0% +$1.35K 0.39% 94
2013
Q4
$6.1M Sell
127,729
-21,039
-14% -$962K 0.34% 105
2013
Q3
$6.76M Sell
148,768
-5,568
-4% -$254K 0.39% 104
2013
Q2
$6.84M Buy
+154,336
New +$6.89M 0.43% 96

Other funds holding MRK

Boston Common Asset Management's MRK Position: Q2 2026 in Review

Boston Common Asset Management reduced its Merck (MRK) stake by 0.23% in Q2 2026, selling an estimated $52.9K and leaving 198,228 shares worth $25.5M. The position accounts for 1.51% of the portfolio, ranked #13.

Boston Common Asset Management first reported a position in MRK in Q2 2013 and has held it in 53 quarters since. The position peaked at $72.2M in Q4 2022. 1,299 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Boston Common Asset Management held 198,228 shares of Merck worth $25.5M as of Q2 2026.
  • Boston Common Asset Management sold 452 Merck shares in Q2 2026, an estimated $52.9K.
  • Merck made up 1.51% of Boston Common Asset Management's portfolio in Q2 2026, its #13 holding.
  • Boston Common Asset Management first reported a position in Merck in Q2 2013 and has held it in 53 quarters since.
  • Boston Common Asset Management's Merck position peaked at $72.2M in Q4 2022.
  • 1,299 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Boston Common Asset Management's 13F filing for Q2 2026, filed 21 Jul 2026.